Shares of Opko Health Inc. (NASDAQ:OPK) gapped down prior to trading on Tuesday . The stock had previously closed at $1.87, but opened at $1.96. Opko Health shares last traded at $2.00, with a volume of 8218717 shares.
Several analysts recently commented on the company. ValuEngine lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Tuesday, April 30th. Finally, Barrington Research reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Opko Health in a report on Thursday, February 28th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $9.25.
The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -8.04 and a beta of 1.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.10 and a quick ratio of 0.96.
Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.08). The company had revenue of $222.50 million for the quarter, compared to analysts’ expectations of $241.27 million. Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. Opko Health’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.08) earnings per share. On average, analysts expect that Opko Health Inc. will post -0.2 EPS for the current fiscal year.
In related news, Director Richard C. Pfenniger, Jr. bought 50,000 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $2.05 per share, for a total transaction of $102,500.00. Following the completion of the transaction, the director now owns 171,310 shares of the company’s stock, valued at $351,185.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Phillip Md Et Al Frost bought 20,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were bought at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $7,917,893.58. The disclosure for this purchase can be found here. Insiders have purchased 2,108,250 shares of company stock worth $4,725,980 over the last quarter. 42.74% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co purchased a new position in shares of Opko Health in the fourth quarter valued at about $30,000. Piedmont Investment Advisors Inc. purchased a new position in shares of Opko Health in the first quarter valued at about $27,000. FDx Advisors Inc. purchased a new position in shares of Opko Health in the fourth quarter valued at about $33,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Opko Health in the first quarter valued at about $39,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 4,846 shares in the last quarter. Institutional investors own 22.66% of the company’s stock.
Opko Health Company Profile (NASDAQ:OPK)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Featured Article: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.